First-in-Class Anti-immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors

PURPOSE: In this first-in-human study (NCT03564691) in advanced solid tumors, we investigated a novel first-in-class human IgG4 monoclonal antibody targeting the immunoglobulin-like transcript 4 (ILT4) receptor, MK-4830, as monotherapy and in combination with pembrolizumab. PATIENTS AND METHODS: Pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Siu, Lillian L., Wang, Ding, Hilton, John, Geva, Ravit, Rasco, Drew, Perets, Ruth, Abraham, Anson K., Wilson, Douglas C., Markensohn, Julia F., Lunceford, Jared, Suttner, Leah, Siddiqi, Shabana, Altura, Rachel A., Maurice-Dror, Corinne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401547/
https://www.ncbi.nlm.nih.gov/pubmed/34598945
http://dx.doi.org/10.1158/1078-0432.CCR-21-2160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401547/
https://www.ncbi.nlm.nih.gov/pubmed/34598945
http://dx.doi.org/10.1158/1078-0432.CCR-21-2160

Ejemplares similares